Skip to main content
Journal of Atrial Fibrillation logoLink to Journal of Atrial Fibrillation
. 2009 Apr 1;1(6):161. doi: 10.4022/jafib.161

Predictors of Success After a First Circumferential Pulmonary Vein Isolation For Atrial Fibrillation

T De Potter 1, R Tavernier 1, D Devos 1, K Van Beeumen 1, M Duytschaever 1
PMCID: PMC5398781  PMID: 28496618

Abstract

Background: To identify and characterise pre-procedural and procedural parameters which predict maintenance of sinus rhythm after a first circumferential pulmonary vein isolation (CPVI) for recurrent atrial fibrillation (AF).

Methods: 100 patients (54±10 yrs) undergoing CARTO-guided CPVI for symptomatic drug refractory, paroxysmal or shortstanding persistent AF were studied. The endpoint was complete electrical isolation within the encircled regions. 3D left atrial (LA) volume was measured by CARTO geometry. Follow-up examinations (symptoms, ECG, 24-hour ECG recording) were performed at 1 and 3 months and every 3 months thereafter.

Results: After the first CPVI, 71 patients (71%) were free of AF without antiarrhythmic drug therapy (follow up:28±11 months). The only independent and significant predictors for freedom of AF after the first CPVI were duration of AF history and 3D LA volume (p<0.05). However, a significant overlap in durations of AF history and 3D LA volumes between failures and successes was observed.

Conclusions: (1) Using the “circumferential pulmonary vein isolation” approach, the first catheter ablation leads to resolution of arrhythmia in ≈ 70% of symptomatic AF patients. (2) Independent predictors for freedom of AF after initial CPVI are duration of AF history and 3D LA volume. (3) Due to considerable overlap between failures and successes, these parameters can not be used to identify patients who should not undergo CPVI or in whom an additional ablation beyond CPVI is required. On the other hand, our results do suggest that an ablation strategy early in the course of AF disease can influence successful outcome.

Introduction

Since the initial identification of the left atrium/pulmonary vein (LA/PV) junction as an important site for initiation and perpetuation of atrial fibrillation (AF), a wide spectrum of catheter-based therapies for treating AF has been developed, mostly using the LA/PV junction as an endocardial RF ablation target.[1-5] Percutaneous catheter ablation is a reasonable alternative to pharmacological therapy to prevent recurrent AF in symptomatic patients with little or no LA enlargement.[6] The common denominator for all procedures and prerequisite for success seems to be achieving long-term electrical isolation of the PVs.[7]

Percutaneous PV isolation (whether ostial or circumferential) is associated with good clinical outcome in 70-90% of the patients with paroxysmal or shortstanding persistent AF.[3-9] Nevertheless, identifying predictors of success is important to (1) avoid a costly, possibly dangerous procedure in patients not suited for this technique (non-responders) or to (2) apply a more complex ablation strategy (additional lines, targeting fractionated electrograms) in selected patients. Although previous studies, reporting on predictors of success after catheter ablation of AF, identified left atrial size as an independent predictor of AF recurrence after catheter ablation, only limited data are available on predictors after circumferential PV isolation (CPVI).[10-26] Moreover, in all studies left atrial size was assessed by 2D transthoracic echocardiograpy.

Therefore we aimed to investigate in a cohort of 100 patients (1) which pre-procedural and procedural characteristics are likely to influence clinical outcome after a single CPVI procedure, (2) whether 3D LA volume -assessed by CARTO geometry can predict clinical outcome after CPVI and (3) whether observed independent predictors can be used to screen out patients who should not undergo CPVI.

Materials and Methods

Patient Data

The patient population consisted of 100 consecutive patients referred for percutaneous catheter ablation of AF between July 2003 and August 2006 ([Table 1]). Each patient had been in follow-up for symptomatic paroxysmal (3.8±2.8 episodes per week) or shortstanding persistent AF. The duration of AF history, defined as the time since first ECG documentation of AF was 6.2±6.4 years. Pharmacological treatment with 2.6±1.0 types of class I and/or III antiarrhythmic drugs (AADs) had not been able to provide symptom control. Arterial hypertension was present in 23%, structural heart disease in 15% of the patients.

Table 1. Patient characteristics.

Legend: AF=atrial fibrillation, AADs=antiarrhythmic drugs, VKA=vitamin K antagonists, LA=left atrium

Age (y) 54 ± 10
Male (N) 83 (83%)
AF type (N)
Paroxysmal 80 (80%)
Persistent 20 (20%)
Duration of AF History (y) 6.2 ± 6.4
Number of AADs (N) 2.6 ± 1.0
Amiodarone (N) 42 (42%)
VKA (N) 47 (47%)
History of endurance sports (N) 10 (10%)
Arterial hypertension (N) 23 (23%)
Structural heart disease (N) 15 (15%)
Ischemic heart disease 5 (5%)
Hypertrophic cardiomyopathy 4 (4%)
Valvular heart disease 4 (4%)
Other (dilated, ethanol) 2 (2%)
3D LA volume (ml, Carto) 92±25

CT Acquisition

Of the 100 patients, 60 underwent an ECG-gated cardiac CT examination prior to the procedure. Equipment selection was done on the basis of availability, with a preference for a 16-slice CT (N=52, 16 slice CT, Philips Brilliance, Best; N=8, 4 slice CT, Siemens Volume Zoom, Erlangen). Depending on the equipment used, ECG gating was set up to acquire images at +75% or -35% of the RR interval, respectively. Contrast injection protocols were optimized for filling all cavities. In 11 patients, metoprolol tartrate 2.5 to 5 mg was used intravenously to slow down sinus rhythm to a target heart rate of 65 bpm.

Left atrial cavities were segmented in the Advantage Workstation software (software version AW Suite 5.5.3e, GE Medical Systems, Milwaukee, WI, USA). Left and right pulmonary veins were morphologically evaluated. Pulmonary ostium morphology was evaluated from an endocavitary point of view as described in the literature: a patient was considered to have distinct pulmonary vein ostia, if the individual PVs entered the atrium at markedly different angles and did not share a common region.[27]

A detailed segmentation of left and right ventricle, left and right atrium, including pulmonary veins, aorta root, pulmonary trunk was performed before the procedure for all CT datasets using a specialised software package (CartoMerge, Biosense Webster, Diamond Bar, CA, USA).

Left Atrial Mapping Procedure

The procedure was performed under general anaesthesia using continuous propofol infusion for sedation, cisatracurium for neuromuscular blockade and remifentanil for analgesia. All patients were in sinus rhythm before and during the procedure. After obtaining vascular access, two 12 French (F) and one 6F sheath were positioned in the right and left femoral vein. A standard 6F steerable decapolar catheter (Bard Electrophysiology) was positioned in the coronary sinus. Two long vascular sheaths (SL0, St Jude Medical) were introduced, via the 12F sheaths, into the right atrium, after which a double trans-septal puncture was performed. Immediately prior to puncture an intravenous loading dose of 10.000IU heparin was given. After puncture a continuous infusion of heparin was started to maintain an activated clotting time (ACT) above 350 seconds. Via the trans-septal sheaths we introduced (1) a deflectable quadripolar 3.5-mm irrigated tip diagnostic/ ablation catheter (NaviStar ThermoCool, Biosense Webster, Johnson & Johnson) and (2) a 10 to 14-pole variable loop mapping catheter. A real-time 3D electro-anatomical map of the LA, including the left atrial appendage, and mitral annulus, was constructed with the use of the non-fluoroscopic navigation system (CARTO, Biosense-Webster, Johnson&Johnson). The PV ostia were identified by fluoroscopic visualisation of the catheter tip during pullback from the PVs, confirmed by simultaneous impedance decrease and the appearance of characteristic LA potentials. In 60 patients, CartoMerge software was used to integrate a CTbased 3D LA surface reconstruction into the virtual electro-anatomical map following three steps: (1) manual alignment of both datasets “with the naked eye” to superimpose the CT image on the CARTO map, (2) automatic visual alignment using 1 landmark on the posterior left superior PVLA junction and (3) surface registration determining the optimal fit between the two datasets by comparing average distance between all points.

Circumferential Pulmonary Vein Isolation

Radiofrequency (RF) energy was delivered in a unipolar mode from the distal electrode of the ablation catheter to a cutaneous patch. Each lesion was created with an application of 20-35W during 30 seconds, with the RF generator (Stockert, Biosense Webster, Johnson & Johnson) with a temperature limit of 48°C. During RF delivery normal saline was infused at a rate of 20 mL/min.

The septal and lateral PVs were encircled 1 to 2 cm away from the ostia (except for the ostial ridge between LSPV and left atrial appendage) by creating point-by-point lesions ([Figure 1], left panel, PA view). In order with the ablation sequence, the circular mapping catheter was positioned at the ostium of the corresponding vein. PV potentials (PVPs) were identified using pacing manoeuvres at the left atrial appendage and distal coronary sinus, by observation of automaticity and by using typical electrogram morphology, as described elsewhere.[28] The end-point of ablation was complete abolishment of local PV electrograms recorded with the mapping catheter (PV isolation). A representative example of PV isolation in the LIPV is shown in [Figure 1] (right panel). In case PVPs remained after anatomical encircling, ablation was applied at the circumference of the ablation circle (at “bridging” potentials), using the circular mapping catheter as a reference to identify the point of earliest breakthrough. After isolation, a waiting time of at least 30 minutes was respected for each vein.

Figure 1. Left panel: Carto-guided PV encircling (PA view). Right panel: example of PV isolation recorded by circular mapping catheter.

Figure 1.

At discharge, anti-arrhythmic drugs (sotalol 80 mg bid or flecainide 100 mg bid) were given for 3 months. Irrespective of CHADS2 risk score for stroke, oral vitamin K antagonist (VKA) therapy was given for at least 3 months with a target INR of 2-3.

Follow-up Evaluation

Each patient was scheduled for routine follow-up examination at 1 and 3 months and every 3 months thereafter. Mean follow-up duration was 28±11 months (range 15 to 59 months). At each follow-up examination, a Holter monitoring was performed. After 3 months of follow-up, anti-arrhythmic drugs were discontinued. If no pre-procedural indication for VKA existed, anticoagulation was stopped as well. CT scanning for the evaluation of PV stenosis was performed in 7 patients exhibiting shortness of breath, coughing or exercise intolerance.

A successful outcome was defined as freedom from both symptomatic and asymptomatic AF, without antiarrhythmic drug therapy, at any follow-up with a blanking period of 1 month. Early recurrence of AF was defined as any recurrence of AF that occurred within the first month after the ablation procedure.

Statistical Analysis

All continuous data are expressed as mean ± standard deviation (SD). Categorical values were compared using the chi-square and Fisher’s exact test. Individual determinants of outcome were analysed with binary logistic regression, entering all theoretical explanatory variables into the model in one step. Student’s t test was used to compare means of 2 normal populations. An alpha level of 0.05 was defined as the threshold for rejecting the null hypothesis. All statistical analyses were performed using the Excel software package (Microsoft, Redmond, USA) and software from the R project for statistical computing (http://www.r-project.org). Receiver operator curves were constructed using Graph Pad Prism 4.0.

Results

Patient Population

Clinical characteristics are given in [Table 1]. Mean 3D LA volume was 92±25 ml on the CARTO map. Based on CT data (N=60), a classical configuration of 2 right-sided pulmonary veins (RPV) was found in 46 (77%) patients and 2 left-sided pulmonary veins in 51 (85%) of patients. A right middle PV was present in 11 (18%) patients, with 4 right PVs in another 3 patients (5%). On the left, a left common PV was found in 6 patients (10%), an additional left middle vein in another 3 (5%) patients.

Mapping And Ablation Data

A 3D electro-anatomical map of the LA was created in 30±12 minutes with an average of 139±32 points. CartoMerge segmentation of all relevant thoracic cavities could be achieved in 12±8 minutes. Registration of the CT dataset with the electrophysiological map was accomplished in all patients. The average point-to-point distance between CARTO and CT surface reconstructions was 2.8±0.6 mm with an average standard deviation of 2.2±0.7 mm.

The average time required for CPVI was 4.4±0.9 hours with a mean fluoroscopy time of 29±16 minutes (radiation dose 136±90 centiGray per cm2). After 115±27 RF applications (RF time 53±10min), electrical isolation was achieved in 384 out of 387 separate PVs (99.2%). Isolation of all PVs could be obtained in 97 out of 100 patients (97%). A significant ablation-induced vagal reflex (defined as sinus bradycardia < 40 bpm, AV block, asystole or hypotension), was observed in 14 patients (14%), preferentially during RF delivery at the left posterior LA-PV junction. Hemodynamically significant pericardial effusion requiring pericardiocentesis developed in 3 patients (3%). We observed one transient thromboembolic stroke.

Clinical Outcome And Predictors Of Success

After the first CPVI, 71 patients (71%) were free of AF without antiarrhythmic drugs. In the group with recurring AF, 5 patients were asymptomatic. An early recurrence of AF (after 12±8 days) was observed in 25 patients (25%). In [table 2] pre-procedural and procedural parameters are compared between patients with a successful and failed first ablation. Age, sex, clinical type of AF, arterial hypertension, structural heart disease or history of endurance sport did not differ between groups. No particular anatomy on CT or the use of CT itself was predictive for clinical outcome after CPVI.

Table 2. Univariate comparison between successful and failed ablation.

Legend: AHT=arterial hypertension, SHD=structural heart disease

Success (N=71) Failure (N=29) p
Age (y) 54.9 ± 9.7 53.5 ± 9.8 0.54
Male (N) 59 (83%) 24 (83%) 0.8
Paroxysmal (N) 58 (82%) 22 (76%) 0.7
AHT (N) 16 (26%) 7 (24%) 0.93
SHD (N) 12 (17%) 4 (14%) 0.93
History of Endurance sports 9 (13%) 2 (7%) 0.63
Duration AF History (y) 5.2 ± 5.1 8.4 ± 7.0 0.03
3D LA volume (ml, Carto) 87.5 ± 22.9 105.8 ± 25.7 0.003

Early recurrence of AF was also not predictive for clinical outcome (17 out of 25 patients with early recurrence were free of AF, 68%). The number of RF applications was not significantly different between the successful and failed ablation group either. The occurrence of an ablation-induced vagal reflex was equal in both groups (14% in both groups). In contrast, duration of AF history was significantly less in the successful group (8.4±7.0y versus 5.2±5.1y, p<0.05, [Table 2]). Similarly, 3D LA volume was significantly smaller in the successful group (105.8±25.7ml versus 87.5±22.9ml, p<0.05). Binary logistic regression analysis, showed that duration of AF history and 3D LA volume were significant and independent predictors of a successful outcome ([Table 3]). However, as plotted in [Figure 2], there is a marked overlap in the durations of AF history and 3D LA volumes between failures and successes. In [Figure 3], the ROC curves for the duration of AF history and 3D LA volume are plotted. Clearly both curves approach the line of identity with an area under curve of respectively 0.64 and 0.66 suggesting a low overall diagnostic accuracy of these tests. Data on sensitivity, specificity, positive predictive value and negative predictive value for different cut off values are given in [table 4]. When the duration of AF history is very short (one year or shorter), CPVI will result in maintenance of normal sinus rhythm during follow up in 92% of the cases (positive predictive value). However, if ablation would only be considered in this subgroup of patients only 20% of the patients with a potentially successful outcome would be treated (sensitivity). Data on 3D left atrial volume are similar: the chance of a successful outcome after CPVI in the presence of a small atrium (80 ml or less) are high (positive predictive value 88%) but this represents only a minority of patients that can potentially be ablated with success (sensitivity 39%). Overall, the negative predictive value of the duration of AF history or 3D LA volume is low (26% to 33%).

Table 3. Logistic regression analysis results, predictors of successful outcome.

Odds ratio 95% Confidence intervals P
Duration of AF History 0.90 0.81-0.99 < 0.05
3D LA volume (ml,Carto) 0.97 0.94-0.99 < 0.05

Figure 2. Duration of AF history and 3D LA volume (Carto) compared between failed and successful CPVI procedures. p < 0.05 for both comparisons.

Figure 2.

Figure 3. ROC-curves for duration of AF history and LA volume suggesting a low overall diagnostic accuracy of these predictors.

Figure 3.

Table 4. Sensitivity, specificity and predictive values for different cut-off values.

Legend: Hx= history, Sens= sensitivity, Spec= specificity, PPV = positive predictive value, NPV negative predictive value

Sens Spec PPV NPV
Duration AF Hx ≤ 1yr 20% 94% 92% 30%
Duration AF Hx ≤ 4yrs 56% 76% 89% 33%
Duration AF Hx ≤ 8yrs 77% 29% 79% 26%
LA volume ≤ 80ml 39% 83% 88% 30%
LA volume ≤ 100ml 66% 50% 80% 32%
LA volume ≤ 120ml 89% 16% 77% 33%

Discussion

Main Findings

Using the “circumferential pulmonary vein isolation” approach, the first catheter ablation leads to resolution of arrhythmia in almost 70% of symptomatic AF patients with an acceptable risk of complications. Duration of AF history and 3D LA volume are the only independent predictors for freedom of AF after the first CPVI, but a significant overlap between failures and successes is observed.

Predictors Of Clinical Outcome After Catheter Ablation Of AF

Previous studies on clinical and procedural predictors for successful ablation of AF (either segmental PV isolation, circumferential PV ablation or circumferential PV isolation) show varying results.[10-26] In [Table 4] we listed all studies identified by comprehensive MedLine search for peerreviewed English original papers published over the last five years reporting on independent predictors of recurrence of AF after catheter ablation. As in our study, age and gender do not influence outcome after catheter ablation of AF, irrespective of the chosen approach. This is in agreement with recent reports on good clinical outcome after catheter ablation of AF in septuagenarians.[29] The presence of short standing persistent AF (in stead of paroxysmal AF) seems not to be a predictor of failure if circumferential PV ablation or isolation is chosen as ablation strategy. In these patients however segmental ostial catheter ablation seems to be less effective when compared to the results of this technique in paroxysmal AF. The presence of arterial hypertension or limited structural heart disease does not influence clinical outcome.

In contrast to our observations, duration of AF history was not a consistent predictor of AF recurrence in other studies. This discrepancy could be explained by the wide range (0.5 to 30 years) in duration of AF history in our study. In six studies, LA size (assessed by 2D transthoracic echocardiography) was a consistent independent predictor of AF recurrence after catheter ablation, irrespective of the chosen strategy.[3,6,8,21,22] These observations are confirmed by our study in which 3D LA volume measured by CARTO geometry, was an independent predictor of recurrence after a first CPVI approach.

The influence of the duration of AF history and 3D LA volume on AF recurrence are in line with results in a AF surgery. Grubitzsch et al reported that AF duration and LA diameter were the only independent predictors of sinus rhythm after ablation of AF in valvular heart surgery independent of the type of valve disease.[30] Likewise, LA size and duration of AF history have also been shown to predict recurrence of AF after electrical cardioversion of AF. Probably both parameters reflect a higher degree of atrial remodeling either due to AF per se (AF-induced remodeling) or progression of underlying structural heart disease. Atrial remodeling promotes perpetuation of the arrhythmia and increases the likelihood of recurrence by electrical, contractile and structural changes.[31] More specifically, Sanders et al showed that atrial remodelling shifts the driver away from the PV regions resulting in non-PV mediated AF.[32,33] As such, percutaneous ablation targeting only the LA/PV region might be insufficient. On the other hand it is possible that the likelehood of reconnection after successful PV isolation is higher in enlarged atria. Data by Sauer et al showed that acute reconnection during an ablation procedure was more likely to occur in larger left atria.[18]

Clinical Implications

Due to considerable overlap between durations of AF history and 3D LA volumes between failures and successes, these parameters can not be used to screen out patients who should not undergo CPVI. Furthermore ROC curves for these two parameters clearly illustrate that no cut-off point with acceptable sensitivity and specificity can be set for any of the two parameters that would identify a subgroup of patients that can be ablated successfully. However, it is clear that patients with a short AF history duration and small 3D LA volume have a high likelihood of success after a single CPVI with no need for any additional ablation targets (AF duration ≤1 years, 92% sinus rhythm during follow up; LA volume ≤ 80 ml, 88% sinus rhythm during follow-up). Of course, this would be applicable to only a minority of patients presenting with AF (20% and 39% respectively). On the other hand our results do support the concept of an early ablation strategy in the course of paroxysmal or short standing persistent AF. This approach is already incorporated in the recent guidelines on the management of AF stating that catheter ablation is an accepted alternative treatment strategy after failure of one single antiarrhythmic drug. Changing to a second anti-arrhythmic drug strategy offers limited benefit and might result in delayed catheter-based intervention.

Furthermore our data imply that, in the presence of enlarged atria or long-lasting AF history, ablation targeting the LA/PV region might not be enough to achieve long-term cure. As such the physician can opt either to avoid possibly hazardous ablation or to perform a more complex ablation (additional linear lesions, fractionated electrograms, non-PV foci). Our data also imply that the decision to extend the procedure can be based upon CARTO guided calculation of 3D LA volume at the beginning of the procedure.

Limitations

The main limitation of our study is that we conducted an observational, albeit prospective investigation. Another limitation is the absence of stringent arrhythmia monitoring after ablation (transtelephonic monitoring, implantable loop recorders). As such patients with asymptomatic recurrences of AF could be miscategorized as being successfully ablated. Finally, not all potential predictors of recurrences of AF were analysed. However, we focused on clinical and periprocedural parameters that can easily be obtained in all patients.

Conclusions

A single circumferential pulmonary vein isolation results in resolution of arrhythmia in ≈70% of patients with paroxysmal or short standing persistent symptomatic AF. Duration of AF history and 3D LA volume are independent predictors of successful outcome but due to considerable overlap between failures and successes, these parameters can not be used to identify patients who should not undergo CPVI or in whom an additional ablation beyond CPVI is required. Our results suggest that an ablation strategy early in the course of AF disease can influence successful outcome.

Disclosures

None.

References

  • 1.Fuster Valentin, Rydén Lars E, Cannom David S, Crijns Harry J, Curtis Anne B, Ellenbogen Kenneth A, Halperin Jonathan L, Le Heuzey Jean-Yves, Kay G Neal, Lowe James E, Olsson S Bertil, Prystowsky Eric N, Tamargo Juan Luis, Wann Samuel, Smith Sidney C, Jacobs Alice K, Adams Cynthia D, Anderson Jeffery L, Antman Elliott M, Halperin Jonathan L, Hunt Sharon Ann, Nishimura Rick, Ornato Joseph P, Page Richard L, Riegel Barbara, Priori Silvia G, Blanc Jean-Jacques, Budaj Andrzej, Camm A John, Dean Veronica, Deckers Jaap W, Despres Catherine, Dickstein Kenneth, Lekakis John, McGregor Keith, Metra Marco, Morais Joao, Osterspey Ady, Tamargo Juan Luis, Zamorano José Luis. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006 Sep;8 (9):651–745. doi: 10.1093/europace/eul097. [DOI] [PubMed] [Google Scholar]
  • 2.Haïssaguerre M, Jaïs P, Shah D C, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998 Sep 03;339 (10):659–66. doi: 10.1056/NEJM199809033391003. [DOI] [PubMed] [Google Scholar]
  • 3.Oral Hakan, Scharf Christoph, Chugh Aman, Hall Burr, Cheung Peter, Good Eric, Veerareddy Srikar, Pelosi Frank, Morady Fred. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation. 2003 Nov 11;108 (19):2355–60. doi: 10.1161/01.CIR.0000095796.45180.88. [DOI] [PubMed] [Google Scholar]
  • 4.Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, Salvati A, Dicandia C, Calabrò M P, Mazzone P, Ficarra E, Di Gioia C, Gulletta S, Nardi S, Santinelli V, Benussi S, Alfieri O. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001 Nov 20;104 (21):2539–44. doi: 10.1161/hc4601.098517. [DOI] [PubMed] [Google Scholar]
  • 5.Haïssaguerre M, Shah D C, Jaïs P, Hocini M, Yamane T, Deisenhofer I, Chauvin M, Garrigue S, Clémenty J. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation. 2000 Nov 14;102 (20):2463–5. doi: 10.1161/01.cir.102.20.2463. [DOI] [PubMed] [Google Scholar]
  • 6.Calkins Hugh, Brugada Josep, Packer Douglas L, Cappato Riccardo, Chen Shih-Ann, Crijns Harry J G, Damiano Ralph J, Davies D Wyn, Haines David E, Haissaguerre Michel, Iesaka Yoshito, Jackman Warren, Jais Pierre, Kottkamp Hans, Kuck Karl Heinz, Lindsay Bruce D, Marchlinski Francis E, McCarthy Patrick M, Mont J Lluis, Morady Fred, Nademanee Koonlawee, Natale Andrea, Pappone Carlo, Prystowsky Eric, Raviele Antonio, Ruskin Jeremy N, Shemin Richard J. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace. 2007 Jun;9 (6):335–79. doi: 10.1093/europace/eum120. [DOI] [PubMed] [Google Scholar]
  • 7.Ouyang Feifan, Bänsch Dietmar, Ernst Sabine, Schaumann Anselm, Hachiya Hitoshi, Chen Minglong, Chun Julian, Falk Peter, Khanedani Afsaneh, Antz Matthias, Kuck Karl-Heinz. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation. 2004 Oct 12;110 (15):2090–6. doi: 10.1161/01.CIR.0000144459.37455.EE. [DOI] [PubMed] [Google Scholar]
  • 8.Pappone C, Oreto G, Lamberti F, Vicedomini G, Loricchio M L, Shpun S, Rillo M, Calabrò M P, Conversano A, Ben-Haim S A, Cappato R, Chierchia S. Catheter ablation of paroxysmal atrial fibrillation using a 3D mapping system. Circulation. 1999 Sep 14;100 (11):1203–8. doi: 10.1161/01.cir.100.11.1203. [DOI] [PubMed] [Google Scholar]
  • 9.Wazni Oussama M, Marrouche Nassir F, Martin David O, Verma Atul, Bhargava Mandeep, Saliba Walid, Bash Dianna, Schweikert Robert, Brachmann Johannes, Gunther Jens, Gutleben Klaus, Pisano Ennio, Potenza Dominico, Fanelli Raffaele, Raviele Antonio, Themistoclakis Sakis, Rossillo Antonio, Bonso Aldo, Natale Andrea. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005 Jun 01;293 (21):2634–40. doi: 10.1001/jama.293.21.2634. [DOI] [PubMed] [Google Scholar]
  • 10.Oral Hakan, Knight Bradley P, Tada Hiroshi, Ozaydin Mehmet, Chugh Aman, Hassan Sohail, Scharf Christoph, Lai Steve W K, Greenstein Radmira, Pelosi Frank, Strickberger S Adam, Morady Fred. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002 Mar 05;105 (9):1077–81. doi: 10.1161/hc0902.104712. [DOI] [PubMed] [Google Scholar]
  • 11.Oral Hakan, Knight Bradley P, Ozaydin Mehmet, Tada Hiroshi, Chugh Aman, Hassan Sohail, Scharf Christoph, Lai Steve W K, Greenstein Radmira, Pelosi Frank, Strickberger S Adam, Morady Fred. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J. Am. Coll. Cardiol. 2002 Jul 03;40 (1):100–4. doi: 10.1016/s0735-1097(02)01939-3. [DOI] [PubMed] [Google Scholar]
  • 12.Chen Michael S, Marrouche Nassir F, Khaykin Yaariv, Gillinov A Marc, Wazni Oussama, Martin David O, Rossillo Antonio, Verma Atul, Cummings Jennifer, Erciyes Demet, Saad Eduardo, Bhargava Mandeep, Bash Dianna, Schweikert Robert, Burkhardt David, Williams-Andrews Michelle, Perez-Lugones Alejandro, Abdul-Karim Ahmad, Saliba Walid, Natale Andrea. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J. Am. Coll. Cardiol. 2004 Mar 17;43 (6):1004–9. doi: 10.1016/j.jacc.2003.09.056. [DOI] [PubMed] [Google Scholar]
  • 13.Vasamreddy Chandrasekhar R, Lickfett Lars, Jayam Vinod K, Nasir Khurram, Bradley David J, Eldadah Zayd, Dickfeld Timm, Berger Ronald, Calkins Hugh. Predictors of recurrence following catheter ablation of atrial fibrillation using an irrigated-tip ablation catheter. J. Cardiovasc. Electrophysiol. 2004 Jun;15 (6):692–7. doi: 10.1046/j.1540-8167.2004.03538.x. [DOI] [PubMed] [Google Scholar]
  • 14.Verma Atul, Wazni Oussama M, Marrouche Nassir F, Martin David O, Kilicaslan Fethi, Minor Stephen, Schweikert Robert A, Saliba Walid, Cummings Jennifer, Burkhardt J David, Bhargava Mandeep, Belden William A, Abdul-Karim Ahmad, Natale Andrea. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J. Am. Coll. Cardiol. 2005 Jan 18;45 (2):285–92. doi: 10.1016/j.jacc.2004.10.035. [DOI] [PubMed] [Google Scholar]
  • 15.Della Bella Paolo, Riva Stefania, Fassini Gaetano, Casella Michela, Carbucicchio Corrado, Trevisi Nicola, Berti Marco, Giraldi Francesco, Maccabelli Giuseppe. Long-term follow-up after radiofrequency catheter ablation of atrial fibrillation: role of the acute procedure outcome and of the clinical presentation. Europace. 2005 Mar;7 (2):95–103. doi: 10.1016/j.eupc.2004.12.008. [DOI] [PubMed] [Google Scholar]
  • 16.Cheema Aamir, Vasamreddy Chandrasekhar R, Dalal Darshan, Marine Joseph E, Dong Jun, Henrikson Charles A, Spragg David, Cheng Alan, Nazarian Saman, Sinha Sunil, Halperin Henry, Berger Ronald, Calkins Hugh. Long-term single procedure efficacy of catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2006 Apr;15 (3):145–55. doi: 10.1007/s10840-006-9005-9. [DOI] [PubMed] [Google Scholar]
  • 17.Jiang Hong, Lu Zhibing, Lei Handong, Zhao Dongdong, Yang Bo, Huang Congxin. Predictors of early recurrence and delayed cure after segmental pulmonary vein isolation for paroxysmal atrial fibrillation without structural heart disease. J Interv Card Electrophysiol. 2006 Apr;15 (3):157–63. doi: 10.1007/s10840-006-9003-y. [DOI] [PubMed] [Google Scholar]
  • 18.Sauer William H, McKernan Melissa L, Lin David, Gerstenfeld Edward P, Callans David J, Marchlinski Francis E. Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm. 2006 Sep;3 (9):1024–8. doi: 10.1016/j.hrthm.2006.05.007. [DOI] [PubMed] [Google Scholar]
  • 19.Pappone Carlo, Santinelli Vincenzo, Manguso Francesco, Vicedomini Gabriele, Gugliotta Filippo, Augello Giuseppe, Mazzone Patrizio, Tortoriello Valter, Landoni Giovanni, Zangrillo Alberto, Lang Christopher, Tomita Takeshi, Mesas Cézar, Mastella Elio, Alfieri Ottavio. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 Jan 27;109 (3):327–34. doi: 10.1161/01.CIR.0000112641.16340.C7. [DOI] [PubMed] [Google Scholar]
  • 20.Vasamreddy Chandrasekhar R, Dalal Darshan, Eldadah Zayd, Dickfeld Timm, Jayam Vinod K, Henrickson Charles, Meininger Glen, Dong Jun, Lickfett Lars, Berger Ronald, Calkins Hugh. Safety and efficacy of circumferential pulmonary vein catheter ablation of atrial fibrillation. Heart Rhythm. 2005 Jan;2 (1):42–8. doi: 10.1016/j.hrthm.2004.10.027. [DOI] [PubMed] [Google Scholar]
  • 21.Berruezo Antonio, Tamborero David, Mont Lluis, Benito Begoña, Tolosana Jose María, Sitges Marta, Vidal Bárbara, Arriagada Germán, Méndez Francisco, Matiello Maria, Molina Irma, Brugada Josep. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur. Heart J. 2007 Apr;28 (7):836–41. doi: 10.1093/eurheartj/ehm027. [DOI] [PubMed] [Google Scholar]
  • 22.Maciel Washington, Andréa Eduardo, Araújo Nilson, Carvalho Hecio, Belo Luiz Gustavo, Siqueira Leonardo, Munhoz Claudio, Cosenza Rodrigo, Mitidieri Fabiana, Atié Jacob. Prognostic criteria of success and recurrence in circumferential ablation for the treatment of atrial fibrillation. Arq. Bras. Cardiol. 2007 Feb;88 (2):134–43. doi: 10.1590/s0066-782x2007000200002. [DOI] [PubMed] [Google Scholar]
  • 23.Seow Swee-Chong, Lim Toon-Wei, Koay Choon-Hiang, Ross David L, Thomas Stuart P. Efficacy and late recurrences with wide electrical pulmonary vein isolation for persistent and permanent atrial fibrillation. Europace. 2007 Dec;9 (12):1129–33. doi: 10.1093/europace/eum219. [DOI] [PubMed] [Google Scholar]
  • 24.Essebag Vidal, Baldessin Ferdinando, Reynolds Matthew R, McClennen Seth, Shah Jignesh, Kwaku Kevin F, Zimetbaum Peter, Josephson Mark E. Non-inducibility post-pulmonary vein isolation achieving exit block predicts freedom from atrial fibrillation. Eur. Heart J. 2005 Dec;26 (23):2550–5. doi: 10.1093/eurheartj/ehi577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Cheema Aamir, Dong Jun, Dalal Darshan, Vasamreddy Chandrasekhar R, Marine Joseph E, Henrikson Charles A, Spragg David, Cheng Alan, Nazarian Saman, Sinha Sunil, Halperin Henry, Berger Ronald, Calkins Hugh. Long-term safety and efficacy of circumferential ablation with pulmonary vein isolation. J. Cardiovasc. Electrophysiol. 2006 Oct;17 (10):1080–5. doi: 10.1111/j.1540-8167.2006.00569.x. [DOI] [PubMed] [Google Scholar]
  • 26.Shin Sung-Hee, Park Mi-Young, Oh Woong-Jin, Hong Soon-Jun, Pak Hui-Nam, Song Woo-Hyuk, Lim Do-Sun, Kim Young-Hoon, Shim Wan-Joo. Left atrial volume is a predictor of atrial fibrillation recurrence after catheter ablation. J Am Soc Echocardiogr. 2008 Jun;21 (6):697–702. doi: 10.1016/j.echo.2007.10.022. [DOI] [PubMed] [Google Scholar]
  • 27.Ahmed Jameel, Sohal Sandeep, Malchano Zachary J, Holmvang Godtfred, Ruskin Jeremy N, Reddy Vivek Y. Three-dimensional analysis of pulmonary venous ostial and antral anatomy: implications for balloon catheter-based pulmonary vein isolation. J. Cardiovasc. Electrophysiol. 2006 Mar;17 (3):251–5. doi: 10.1111/j.1540-8167.2005.00339.x. [DOI] [PubMed] [Google Scholar]
  • 28.Tada Hiroshi, Oral Hakan, Greenstein Radmira, Pelosi Frank, Knight Bradley P, Strickberger S Adam, Morady Fred. Differentiation of atrial and pulmonary vein potentials recorded circumferentially within pulmonary veins. J. Cardiovasc. Electrophysiol. 2002 Feb;13 (2):118–23. doi: 10.1046/j.1540-8167.2002.00118.x. [DOI] [PubMed] [Google Scholar]
  • 29.Corrado Andrea, Patel Dimpi, Riedlbauchova Lucie, Fahmy Tamer S, Themistoclakis Sakis, Bonso Aldo, Rossillo Antonio, Hao Steven, Schweikert Robert A, Cummings Jennifer E, Bhargava Mandeep, Burkhardt David, Saliba Walid, Raviele Antonio, Natale Andrea. Efficacy, safety, and outcome of atrial fibrillation ablation in septuagenarians. J. Cardiovasc. Electrophysiol. 2008 Aug;19 (8):807–11. doi: 10.1111/j.1540-8167.2008.01124.x. [DOI] [PubMed] [Google Scholar]
  • 30.Grubitzsch Herko, Beholz Sven, Dohmen Pascal M, Dushe Simon, Liu Jianshi, Konertz Wolfgang. Ablation of atrial fibrillation in valvular heart surgery: are results determined by underlying valve disease? J. Heart Valve Dis. 2007 Jan;16 (1):76–83. [PubMed] [Google Scholar]
  • 31.Allessie Maurits, Ausma Jannie, Schotten Ulrich. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 2002 May;54 (2):230–46. doi: 10.1016/s0008-6363(02)00258-4. [DOI] [PubMed] [Google Scholar]
  • 32.Sanders Prashanthan, Berenfeld Omer, Hocini Mélèze, Jaïs Pierre, Vaidyanathan Ravi, Hsu Li-Fern, Garrigue Stéphane, Takahashi Yoshihide, Rotter Martin, Sacher Fréderic, Scavée Christophe, Ploutz-Snyder Robert, Jalife José, Haïssaguerre Michel. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation. 2005 Aug 09;112 (6):789–97. doi: 10.1161/CIRCULATIONAHA.104.517011. [DOI] [PubMed] [Google Scholar]
  • 33.Sanders Prashanthan, Nalliah Chrishan J, Dubois Rémi, Takahashi Yoshihide, Hocini Mélèze, Rotter Martin, Rostock Thomas, Sacher Fréderic, Hsu Li-Fern, Jönsson Anders, O'Neill Mark D, Jaïs Pierre, Haïssaguerre Michel. Frequency mapping of the pulmonary veins in paroxysmal versus permanent atrial fibrillation. J. Cardiovasc. Electrophysiol. 2006 Sep;17 (9):965–72. doi: 10.1111/j.1540-8167.2006.00546.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Atrial Fibrillation are provided here courtesy of CardioFront, LLC

RESOURCES